Home page Home page

Translarna
ataluren

Package leaflet: Information for the patient


Translarna 125 mg granules for oral suspension Translarna 250 mg granules for oral suspension Translarna 1000 mg granules for oral suspension ataluren


imageThis medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.


Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.


  1. How to store Translarna


    Keep this medicine out of the sight and reach of children.


    Do not use this medicine after the expiry date, which is stated on the carton and sachet after ‘EXP’. The expiry date refers to the last day of that month.


    This medicine does not require any special storage conditions.


    Take each prepared dose immediately after preparation. Discard the prepared dose if not taken within 24 hours of preparation if kept refrigerated (2 – 8 °C), or within 3 hours at room temperature

    (15 - 30 °C).


    Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


  2. Contents of the pack and other information What Translarna contains

Translarna is available in 3 strengths, each containing 125 mg, 250 mg and 1000 mg of the active substance, called ataluren. The other ingredients are: polydextrose (E1200), macrogol, poloxamer, mannitol (E421), crospovidone, hydroxyethyl cellulose, artificial vanilla flavour (maltodextrin, artificial flavours and propylene glycol), silica, colloidal anhydrous (E551), magnesium stearate.


What Translarna looks like and contents of the pack

Translarna is white to off-white granules for oral suspension in sachets. Translarna is available in packs containing 30 sachets.


Marketing Authorisation Holder PTC Therapeutics International Limited 5th Floor

3 Grand Canal Plaza Grand Canal Street Upper Dublin 4

D04 EE70

Ireland


image

Manufacturer

Almac Pharma Services

22 Seagoe Industrial Estate Craigavon BT63 5QD United Kingdom

PTC Therapeutics International Limited 5th Floor

3 Grand Canal Plaza Grand Canal Street Upper Dublin 4

D04 EE70

Ireland


Almac Pharma Services (Ireland) Limited Finnabair Industrial Estate

Dundalk, Co. Louth, A91P9KD Ireland


image

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


AT, BE, BG, CY, CZ, DK, DE, EE, EL, ES,

HR, HU, IE, IS, IT, LT, LU, LV, MT, NL, NO,

PL, PT, RO, SI, SK, FI, SE, UK (NI)

PTC Therapeutics International Ltd. (Ireland)

+353 (0)1 447 5165

medinfo@ptcbio.com

FR

PTC Therapeutics France Tel: +33(0)1 76 70 10 01

medinfo@ptcbio.com


This leaflet was last revised in


This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.

The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.


There are also links to other websites about rare diseases and treatments.